Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.
about
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapiesIPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity.MDA5 complements TLR3 in suppression of neuroblastomaGEN-27, a Newly Synthetic Isoflavonoid, Inhibits the Proliferation of Colon Cancer Cells in Inflammation Microenvironment by Suppressing NF-κB Pathway.Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.Functional RIG-I-like receptors control the survival of mesenchymal stem cellsMicroenvironmental clues for glioma immunotherapy.Concise reviews: cancer stem cells: from concept to cure.Engineering better immunotherapies via RNA interferenceTumor suppressor activity of RIG-I.Discriminating self from non-self in nucleic acid sensing.RIG-I activation induces the release of extracellular vesicles with antitumor activity.Recombinant Poliovirus for Cancer Immunotherapy.A minimal RNA ligand for potent RIG-I activation in living mice.Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs.Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.
P2860
Q35782820-6FCB8116-5905-4F88-ADD6-C6F7D18DC5CFQ36346936-ED349A14-FC4F-468F-8FCC-8447A26D1F6AQ36413073-F2244460-C993-48E3-A794-011EC455D118Q36661369-8EFE85FC-5BF1-42EB-8BCF-DD80C21B61B5Q36917887-BEB253BB-E309-41FE-A3E3-6C1E3C636831Q36987499-0733EF6B-E993-49A5-ACEF-E915A31ED460Q37424134-CA205469-3FB1-493D-A3C3-E329CEB8CD0AQ38194054-540EAA57-3C69-4473-AA4A-1EBDBFF02576Q38235552-14D5ADFA-04CA-4A55-A71E-578453552960Q38284703-755939D4-4C5B-48C5-87BA-A93BD8FCA54FQ38866734-3CC02D1D-0632-43FB-8D6D-DC4A572F1CD3Q38907820-65F09764-B64B-4C52-AD29-3DA53D615B09Q39181844-D79A3036-8885-45DE-A927-C1E1EB947022Q48508304-0A8ED4A7-99A4-45FE-BACF-D62AFCEA153BQ50335102-FF4FB51E-9781-4D2B-A151-54737E41CD47Q50423292-60F8F6B0-1A8A-432F-AA34-9FEB16CADE8DQ53382317-6D668D71-48EA-414C-882E-2AB893AD9B51Q55508841-A3CCDB28-876B-4DE6-9F90-56C9E8A7E104
P2860
Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@en
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@nl
type
label
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@en
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@nl
prefLabel
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@en
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeting the cytosolic innate ...... heterogeneity in glioblastoma.
@en
P2093
Anja Wieland
Annette Pusch
Björn Scheffler
Christoph Coch
Daniel Trageser
Juliane Dassler
Kristin Roy
Marec Von Lehe
Martin Glas
Matthias Simon
P2860
P304
P356
10.1002/STEM.1350
P577
2013-06-01T00:00:00Z